Morgan Stanley raised the firm’s price target on Bright Horizons to $61 from $57 and keeps an Underweight rating on the shares. The firm, which notes that the stock has outperformed year-to-date and that its valuation is now at pre-COVID levels, sees risk to growth from new centers, tuition, and enrollment and looks to negative estimate revisions as a catalyst, noting that shares are up 43% year-to-date despite consensus EBITDA revisions of negative 2%.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BFAM:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Fly Insider: Kinnate Biopharma, Arrowhead among week’s notable insider trades
- Bright Horizons backs FY23 EPS view $2.80-$3.00, consensus $2.84
- Bright Horizons reports Q1 adjusted EPS 49c, consensus 39c